Hyperlactataemia and lactic acidosis during antiretroviral therapy: Relevance, reproducibility and possible risk factors

AIDS

Volumn 16, Issue 10, 2002, Pages 1341-1349

  Moyle, Graeme J ^a   Datta, Debasis ^a   Mandalia, Sundhiya ^a   Morlese, John ^a   Asboe, David ^a   Gazzard, Brian G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Hyperlactataemia; Lactate acidosis; Lacute

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; METFORMIN; MITOCHONDRIAL DNA; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; LACTIC ACID; THYMIDINE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REPRODUCIBILITY; RISK FACTOR; TREATMENT OUTCOME; VIRUS INFECTION; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ECONOMICS; LONGITUDINAL STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; SEX DIFFERENCE;

ACIDOSIS, LACTIC; ADULT; ANTI-HIV AGENTS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDIES; DIDANOSINE; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMAN; LACTIC ACID; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEX FACTORS; THYMIDINE; HUMANS;

EID: 0037024753     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200207050-00005     Document Type: Article

References (17)

1. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
2. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs)
3. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options
4. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
5. Chronic hyperlacatemia in HIV-infected patients taking antiretroviral therapy
6. Symptomatic hyperlacatemia: An emerging complication of antiretroviral therapy
7. Management of hyperlacatemia: No need for routine lactate measurements
8. Mitochondrial toxicity hypothesis for lipoatrophy: A refutation
9. Effects of hyperinsulinaemia and hyperglycaemia on lactate release and local blood flow in subcutaneous adipose tissue of healthy humans
10. +-ATPase in the insulin-induced lactate release by skeletal muscle
11. Sreening for nucleoside-assocaited lactic acidosis
12. Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study
13. Contra-indications to metformin therapy are largely disregarded
14. Lactic acidosis update for critical care clinicians
15. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
16. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells
17. Increased long-term mitochondrial toxicity with pyrimidine nucleoside combinations